Company poised to conduct additional trials, develop pipeline of technology. Patient experience is a major factor in these MIGS and dry eye innovations.
With a goal of becoming an innovator in minimally invasive glaucoma surgery (MIGS) and procedure-based dry eye treatments, Sight Sciences earlier this year completed a $56 million round of growth capital funding, which will be used to accelerate the growth of the company’s OMNI surgical system and its TearCare system in the United States.
The funding also will help develop a global commercial infrastructure to conduct additional clinical trials and to develop a pipeline of innovations. Sight Sciences was founded by two brothers—Paul Badawi, who had a background in investing in medical device companies, and David Badawi, MD, an ophthalmologist.
In 2006, while attending the American Society of Cataract and Refractive Surgery annual meeting, they decided they could do some good for patients by innovating devices to treat the underlying disease state of prevalent diseases.
They settled on glaucoma and dry eye as areas of focus, recognizing the unmet need in those diseases, and began to develop ideas. In 2011, the brothers incorporated Sight Sciences, and began to raise funds to develop products and bring them to market.
Soon after, the commercial infrastructure was created, and the company moved toward a strong commercial focus. The company’s overall goal is “treating the underlying disease state with innovative products that surgeons and eyecare providers want to use, therefore bringing these innovations to more patients,” said Shawn O’Neil, chief commercial officer.
The company’s focus in this area is evident through OMNI’s ability to target the three potential points of resistance in the conventional outflow pathway (Schlemm’s canal, the distal collector channels, and the trabecular meshwork) with a single, disposable device, whereas TearCare’s approach allows for eyecare professionals to deliver targeted heat to the meibomian glands with a personalized, open-eye experience, allowing the patients to keep their eyes open and blink during the procedure, he noted.
Related: Which MIGS for which patient?